X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company will fund the ongoing clinical development of its three lead candidates, IMU-838 (vidofludimus calcium), a small molecule investigational drug in development as an oral next generation treatment option for patients with multiple sclerosis, IMU-856 and IMU-381.
Lead Product(s): Vidofludimus calcium anhydrous
Therapeutic Area: Neurology Product Name: IMU-838
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BVF Partners
Deal Size: $240.0 million Upfront Cash: $80.0 million
Deal Type: Private Placement January 05, 2024
Details:
IMU-838 (vidofludimus calcium) is a small molecule investigational drug in development as an oral next-generation treatment option for patients with multiple sclerosis and other chronic inflammatory and autoimmune diseases.
Lead Product(s): Vidofludimus calcium anhydrous
Therapeutic Area: Neurology Product Name: IMU-838
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
IMU-838 (vidofludimus calcium) is a small molecule investigational drug in development as an oral next-generation treatment option for patients with multiple sclerosis and other chronic inflammatory and autoimmune diseases.
Lead Product(s): Vidofludimus calcium anhydrous
Therapeutic Area: Neurology Product Name: IMU-838
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2023
Details:
IMU-856 is an orally available and systemically acting small molecule modulator that targets a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. It is being investigated for celiac disease.
Lead Product(s): IMU-856
Therapeutic Area: Gastroenterology Product Name: IMU-856
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2023
Details:
IMU-838 (vidofludimus calcium) inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme for highly metabolically activated T and B immune cells experience metabolic stress, its inhibition results in less pro-inflammatory cytokines and thereby reduce the inflammation.
Lead Product(s): Vidofludimus calcium anhydrous
Therapeutic Area: Gastroenterology Product Name: IMU-838
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
IMU-838 (vidofludimus calcium) is an investigational drug in development as an orally available, next-generation selective immune modulator that is designed to inhibit the intracellular metabolism of activated immune cells by blocking the enzyme DHODH.
Lead Product(s): Vidofludimus calcium anhydrous
Therapeutic Area: Neurology Product Name: IMU-838
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
IMU-935 is a highly potent and selective inverse agonist of RORγ/RORγt (retinoic acid receptor-related orphan nuclear receptor gamma / truncated).
Lead Product(s): IMU-935
Therapeutic Area: Dermatology Product Name: IMU-935
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2022
Details:
The Company intends to use net proceeds from the financing to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes.
Lead Product(s): Vidofludimus calcium anhydrous
Therapeutic Area: Neurology Product Name: IMU-838
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SVB Securities
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 10, 2022
Details:
The Company intends to use net proceeds from the financing to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes.
Lead Product(s): IMU-935
Therapeutic Area: Oncology Product Name: IMU-935
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: SVB Securities
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 10, 2022
Details:
IMA203 T cells are directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma, a protein frequently expressed in large variety of solid cancers, thereby supporting programs’ potential to address a broad cancer patient population.
Lead Product(s): IMA203,Nivolumab
Therapeutic Area: Oncology Product Name: IMA203
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
